Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injecti...
FDA Recall #D-0251-2026 — Class II — December 18, 2025
Product Description
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Reason for Recall
Presence of particulate matter - Glass like particles.
Recalling Firm
Imprimis NJOF, LLC — Ledgewood, NJ
Classification
Class II — May cause temporary or medically reversible adverse health consequences.
Product Type
Drugs
Product Quantity
314 boxes of 6,280 pre-filled syringes
Distribution
U.S Nationwide
Code Information
Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.
Status
Ongoing
Voluntary / Mandated
Voluntary: Firm initiated